142 related articles for article (PubMed ID: 38642032)
1. Should HLA and HPA-matched platelet transfusions for patients with Glanzmann Thrombasthenia or Bernard-Soulier syndrome be standardized care? A Dutch survey and recommendations.
Huisman EJ; Holle N; Schipperus M; Cnossen MH; de Haas M; Porcelijn L; Zwaginga JJ
Transfusion; 2024 May; 64(5):824-838. PubMed ID: 38642032
[TBL] [Abstract][Full Text] [Related]
2. Detection of alloimmunization in Glanzmann Thrombasthenia and Bernard-Soulier Syndrome: Data from a Brazilian Center.
Gabe C; Ziza KC; Durazzo N; Pagani FM; Oliveira VB; Conrado MAV; Dezan MR; Mendrone A; Villaça PR; Dinardo CL; Rocha V
Hematol Transfus Cell Ther; 2023 Jul; 45 Suppl 2(Suppl 2):S101-S107. PubMed ID: 36114116
[TBL] [Abstract][Full Text] [Related]
3. Iron deficiency anemia and bleeding management in pediatric patients with Bernard-Soulier syndrome and Glanzmann Thrombasthenia: A single-institution analysis.
Lee A; Maier CL; Batsuli G
Haemophilia; 2022 Jul; 28(4):633-641. PubMed ID: 35412688
[TBL] [Abstract][Full Text] [Related]
4. How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults.
Grainger JD; Thachil J; Will AM
Br J Haematol; 2018 Sep; 182(5):621-632. PubMed ID: 30117143
[TBL] [Abstract][Full Text] [Related]
5. Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran.
Afrasiabi A; Artoni A; Karimi M; Peyvandi F; Ashouri E; Mannucci PM
Clin Lab Haematol; 2005 Oct; 27(5):324-7. PubMed ID: 16178914
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
[TBL] [Abstract][Full Text] [Related]
7. Alloimmunization in Congenital Deficiencies of Platelet Surface Glycoproteins: Focus on Glanzmann's Thrombasthenia and Bernard-Soulier's Syndrome.
Poon MC; d'Oiron R
Semin Thromb Hemost; 2018 Sep; 44(6):604-614. PubMed ID: 29879742
[TBL] [Abstract][Full Text] [Related]
8. Survival and function of transfused platelets. Studies in two patients with congenital deficiencies of platelet membrane glycoproteins.
Cesar JM; Vecino AM
Platelets; 2009 May; 20(3):158-62. PubMed ID: 19437332
[TBL] [Abstract][Full Text] [Related]
9. Use of HLA- and HPA--matched platelets in alloimmunized patients.
Kekomäki R
Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
[TBL] [Abstract][Full Text] [Related]
10. Elevated CD9 expression as a potential biomarker for diagnosis of Bernard-Soulier syndrome.
Sharifi MJ; Vakili E; Ilkhanipoor H; Zekavat OR; Bordbar M
Blood Coagul Fibrinolysis; 2022 Apr; 33(3):159-161. PubMed ID: 35165218
[TBL] [Abstract][Full Text] [Related]
11. Successful management of perioperative hemostasis in a patient with Glanzmann thrombasthenia who underwent a right total mastectomy.
Ogawa Y; Kunishima S; Yanagisawa K; Osaki Y; Uchiyama Y; Matsumoto N; Tokiniwa H; Horiguchi J; Nojima Y; Handa H
Int J Hematol; 2017 Feb; 105(2):221-225. PubMed ID: 27696190
[TBL] [Abstract][Full Text] [Related]
12. Inherited platelet disorders including Glanzmann thrombasthenia and Bernard-Soulier syndrome.
Diz-Küçükkaya R
Hematology Am Soc Hematol Educ Program; 2013; 2013():268-75. PubMed ID: 24319190
[TBL] [Abstract][Full Text] [Related]
13. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
[TBL] [Abstract][Full Text] [Related]
14. Treatment of inherited platelet disorders.
Seligsohn U
Haemophilia; 2012 Jul; 18 Suppl 4():161-5. PubMed ID: 22726101
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
16. Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions.
Devecioğlu O; Unüvar A; Anak S; Bilge I; Ander H; Ziylan O
Turk J Pediatr; 2003; 45(1):64-6. PubMed ID: 12718376
[TBL] [Abstract][Full Text] [Related]
17. Immunization against α
Fiore M; Bayat B; Phuangtham R; Blouin L; Huguenin Y; Bein G; Santoso S
J Thromb Haemost; 2021 Jan; 19(1):255-261. PubMed ID: 33090654
[TBL] [Abstract][Full Text] [Related]
18. New Insights Into the Treatment of Glanzmann Thrombasthenia.
Poon MC; Di Minno G; d'Oiron R; Zotz R
Transfus Med Rev; 2016 Apr; 30(2):92-9. PubMed ID: 26968829
[TBL] [Abstract][Full Text] [Related]
19. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.
Poon MC; Zotz R; Di Minno G; Abrams ZS; Knudsen JB; Laurian Y
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S33-6. PubMed ID: 16427383
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of allo-immunization anti-HLA and anti-integrin alphaIIbbeta3 in Glanzmann Thromboasthenia patients.
Santoro C; Rago A; Biondo F; Conti L; Pulcinelli F; Laurenti L; Perrone MP; Baldacci E; Leporace A; Mazzucconi MG
Haemophilia; 2010 Sep; 16(5):805-12. PubMed ID: 20345392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
